Index Entries

Bruce K. Patterson, Edgar B. Francisco, Ram Yogendra, Emily Long, Amruta Pise, Christopher Beaty, Eric Osgood, John Bream, Mark Kreimer, Richard Vander Heide, Jose Guevara-Coto, Rodrigo Mora, and Javier Mora
July 12, 2022
IncellDx, Inc.

This is a preprint; it has not been peer reviewed by a journal.

“Background: We sought to determine the immunologic abnormalities in patients following SARS-CoV-2 vaccines who experience post-acute sequelae of COVID-19 (PASC)-like symptoms?>?4 weeks post vaccination. In addition, we investigated whether the potential etiology was similar to PASC [a.k.a., long COVID]…

Results: We determined that post-vaccination individuals with PASC-like symptoms had similar symptoms to PASC patients. When analyzing their immune profile, post-vaccination individuals had statistically significant elevations of sCD40L, CCL5, IL-6, and IL-8. SARS-CoV-2 S1 and S2 protein were detected in CD16?+?monocytes using flow cytometry and mass spectrometry on sorted cells.

Conclusions: Post-vaccination individuals with PASC-like symptoms exhibit markers of platelet activation and pro-inflammatory cytokine production which may be driven by the persistence of SARS-CoV-2 S1 protein persistence in intermediate and non-classical monocytes.”

document
COVID-19,vaccine systemic and virological concerns,mRNA,SARS-CoV-2 spike protein,vaccines